Prostate Cancer News and Research

Latest Prostate Cancer News and Research

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth.

12 Oct 2015

IU investigators find how cancer-induced bone destruction triggers skeletal muscle weakness

Cancer researchers at Indiana University and their colleagues have discovered how cancer-induced bone destruction causes skeletal muscle weakness.

12 Oct 2015

Study identifies four distinct types of bowel cancer

Bowel cancer can be divided up into four distinct diseases, each with its own set of biological characteristics, a major new study reports.

12 Oct 2015

YK-4-279 compound works against some forms of leukemia: Study

A compound discovered and developed by a team of Georgetown Lombardi Comprehensive Cancer Center researchers that halts cancer in animals with Ewing sarcoma and prostate cancer appears to work against some forms of leukemia, too.

12 Oct 2015

Scientists create first 3-D image of key protein involved in development of cancers

Scientists from New Zealand and Australia have created the first three-dimensional image of a key protein involved in the development of blood and other cancers.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

6 Oct 2015

Novel technique may help women and their oncologists choose options for treating breast cancer

Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease.

30 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping or loss of bladder control may emerge when the disease advances as a signal to men to take action with their doctors.

29 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

29 Sep 2015

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Giving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research* presented at the 2015 European Cancer Congress today (Monday).

28 Sep 2015

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

IU investigators find how cancer-induced bone destruction triggers skeletal muscle weakness

Study identifies four distinct types of bowel cancer

YK-4-279 compound works against some forms of leukemia: Study

Scientists create first 3-D image of key protein involved in development of cancers

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Recipients of 2015 Ferring Innovation Grants announced

Researchers study effect of immune tolerance on certain cancer risks

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Novel technique may help women and their oncologists choose options for treating breast cancer

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New global educational initiative helps men identify symptoms of advanced prostate cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

Fewer, higher doses of radiotherapy effective at treating prostate cancer

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in